Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Lexaria Bioscience stock | $6.45
Learn how to easily invest in Lexaria Bioscience stock.
Lexaria Bioscience, a Kelowna, Canada-based company that develops drug delivery platforms, is seeking a listing on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker "LXRP," as well as the Canadian Securities Exchange under the ticker symbol "LXX."
How to buy shares in Lexaria Bioscience
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LEXX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Lexaria Bioscience stock price (NASDAQ: LEXX)Use our graph to track the performance of LEXX stocks over time.
Lexaria Bioscience shares at a glance
|Latest market close||$6.45|
|52-week range||$4.11 - $10.50|
|50-day moving average||$6.55|
|200-day moving average||$6.24|
|Wall St. target price||$12.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.97|
Buy Lexaria Bioscience shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Lexaria Bioscience stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lexaria Bioscience price performance over time
|1 week (2021-10-19)||-5.29%|
|1 month (2021-09-24)||-5.98%|
|3 months (2021-07-26)||-4.73%|
|6 months (2021-04-26)||21.70%|
|1 year (2020-10-26)||3,386.49%|
|2 years (2019-10-25)||821.43%|
|3 years (2018-10-26)||330.00%|
|5 years (2016-10-26)||2,171.13%|
Lexaria Bioscience financials
|Gross profit TTM||$276,925|
|Return on assets TTM||-42.56%|
|Return on equity TTM||-54.36%|
|Market capitalisation||$37.7 million|
TTM: trailing 12 months
Shorting Lexaria Bioscience shares
There are currently 338,984 Lexaria Bioscience shares held short by investors – that's known as Lexaria Bioscience's "short interest". This figure is 5.5% down from 358,862 last month.
There are a few different ways that this level of interest in shorting Lexaria Bioscience shares can be evaluated.
Lexaria Bioscience's "short interest ratio" (SIR)
Lexaria Bioscience's "short interest ratio" (SIR) is the quantity of Lexaria Bioscience shares currently shorted divided by the average quantity of Lexaria Bioscience shares traded daily (recently around 325946.15384615). Lexaria Bioscience's SIR currently stands at 1.04. In other words for every 100,000 Lexaria Bioscience shares traded daily on the market, roughly 1040 shares are currently held short.
To gain some more context, you can compare Lexaria Bioscience's short interest ratio against those of similar companies.
However Lexaria Bioscience's short interest can also be evaluated against the total number of Lexaria Bioscience shares, or, against the total number of tradable Lexaria Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexaria Bioscience's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Lexaria Bioscience shares in existence, roughly 60 shares are currently held short) or 0.0726% of the tradable shares (for every 100,000 tradable Lexaria Bioscience shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lexaria Bioscience.
Find out more about how you can short Lexaria Bioscience stock.
Lexaria Bioscience share dividends
We're not expecting Lexaria Bioscience to pay a dividend over the next 12 months.
You may also wish to consider:
- Pfizer (PFE.US) (3.59% forward annual dividend yield)
Have Lexaria Bioscience's shares ever split?
Lexaria Bioscience's shares were split on a 1:30 basis on 11 January 2021. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexaria Bioscience shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Lexaria Bioscience shares which in turn could have impacted Lexaria Bioscience's share price.
Lexaria Bioscience share price volatility
Over the last 12 months, Lexaria Bioscience's shares have ranged in value from as little as $4.11 up to $10.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexaria Bioscience's is 1.5079. This would suggest that Lexaria Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Lexaria Bioscience's beta into context you can compare it against those of similar companies.
Lexaria Bioscience overview
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. .
Lexaria Bioscience in the news
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.'s Technology as an Alternative to Smoking and Vaping
Lexaria Bioscience Corp.'s DehydraTECH(TM) Impacting the Pharmaceutical Industry
Lexaria THC Test Results Come in as MORE Act Gains Momentum in Congress
Frequently asked questionsWhat percentage of Lexaria Bioscience is owned by insiders or institutions?
Currently 16.775% of Lexaria Bioscience shares are held by insiders and 8.177% by institutions. How many people work for Lexaria Bioscience?
Latest data suggests 4 work at Lexaria Bioscience. When does the fiscal year end for Lexaria Bioscience?
Lexaria Bioscience's fiscal year ends in August. Where is Lexaria Bioscience based?
Lexaria Bioscience's address is: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 What is Lexaria Bioscience's ISIN number?
Lexaria Bioscience's international securities identification number is: US52886N4060
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert